Get the Stockscreener App
25.55
1.09%
-0.275
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.55, with a volume of 11.45M.
It is down -1.09% in the last 24 hours and down -5.83% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.83
Open:
$25.86
24h Volume:
11.45M
Relative Volume:
0.28
Market Cap:
$146.38B
Revenue:
$63.63B
Net Income/Loss:
$8.03B
P/E Ratio:
18.12
EPS:
1.41
Net Cash Flow:
$8.23B
1W Performance:
-3.66%
1M Performance:
-5.83%
6M Performance:
-11.44%
1Y Performance:
-7.30%
1-Day Range:
$25.53
$25.96
1-Week Range:
$25.54
$26.92
52-Week Range:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.56 | 146.38B | 63.63B | 8.03B | 8.23B | 1.41 |
|
LLY
Lilly Eli Co
|
879.46 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
86.44 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.74 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
191.93 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
87.94 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Join Pfizer in the Fight Against Cancer - Pfizer
Pfizer Prepares To 'Knock Out' Cancer In Super Bowl Spot 02/07/2025 - MediaPost Communications
Pfizer to air second Super Bowl ad, doubling down on fight against cancer - MM+M Online
Lecap Asset Management Ltd. Sells 12,439 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Golden State Wealth Management LLC Takes $857,000 Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Full Year 2024 Earnings: EPS Misses Expectations - Simply Wall St
Leerink Partnrs Has Negative Estimate for Pfizer Q3 Earnings - MarketBeat
Sumitomo Mitsui Trust Group Inc. Acquires 956,873 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
RNC Capital Management LLC Lowers Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Ledyard National Bank Has $5.44 Million Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Stratos Wealth Advisors LLC Sells 58,510 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Brokers Issue Forecasts for Pfizer’s Q1 Earnings (NYSE:PFE) - Defense World
Gummy Vitamins Market growing at a CAGR of 5.9% from 2023 to 2032 | Pharmavite, Pfizer Inc., Unilever PLC - EIN News
Pfizer Stock: Q4 Surge Despite Market Dip - sharewise
Is Pfizer Inc. (PFE) the Best Dividend Stock With 5% Yield? - Insider Monkey
Pfizer lures Novartis exec to be its chief oncology officer - The Pharma Letter
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - AL.com
Pfizer taps former Novartis exec to lead cancer drug push - BioPharma Dive
Pain Relief Medication Market Expected to Reach by 2031 | Pfizer - openPR
Injectable Drugs Market Is Booming Worldwide 2025-2032 | Pfizer Inc.. Cipla Inc., Sanofi S.A., GlaxoSmithKline - EIN News
Biosimilar Pipeline Analysis Market Detailed in New Research Report By 2032 | Biocon, Pfizer Inc, Merck & Co. - EIN News
Florida secures $2.3 million in settlement with Pfizer over Medicaid fraud allegations - Florida’s Voice
Car T Cell Therapy Market Projected To Witness Substantial Growth, 2025-2032 | Pfizer, bluebird bio, Johnson & - EIN News
Covid Products Drove Pfizer's Fourth Quarter. Is It Now A Buy? - Investor's Business Daily
Pfizer Inc. (NYSE:PFE) Q4 2024 Earnings Call Transcript - Insider Monkey
Daiwa Securities Adjusts Price Target on Pfizer to $30 From $28, Keeps Outperform Rating - Marketscreener.com
Pfizer Inc. Reports Q4 2024 Earnings: EPS of $0.63 and Revenue o - GuruFocus.com
Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & More - GlobeNewswire Inc.
Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga - AOL
Pfizer taps a former Novartis exec to lead cancer drug push - Yahoo Finance
Fast Melt Tablets Market Overall Study Report 2025-2032 | Pfizer - openPR
Attorney General's Office secures $2.3 million in multistate action from Pfizer-owned company - Florida Politics
Pfizer’s 2024 Earnings Call: Strong Performance and Strategic Growth - TipRanks
What's Going On With Pfizer Shares Wednesday? - Benzinga
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck - Yahoo Finance
PFIZER INC : Receives a Buy rating from DZ Bank -February 05, 2025 at 01:29 pm EST - Marketscreener.com
January Social Media Round-Up—World Economic Forum, ASCO GI, and More - Pfizer
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb - BioPharma Dive
UBS Adjusts Price Target on Pfizer to $28 From $29, Maintains Neutral Rating -February 05, 2025 at 10:02 am EST - Marketscreener.com
Citigroup Adjusts Price Target on Pfizer to $27 From $29, Maintains Neutral Rating -February 05, 2025 at 06:36 am EST - Marketscreener.com
US-based drugmaker Pfizer reports Q4 2024 net income of $410m - World Pharmaceutical Frontiers
(02/05/25) Top Picks 2025: Pfizer (PFE) - Moneyshow.com
PFIZER INC : Gets a Neutral rating from JP Morgan -February 05, 2025 at 05:52 am EST - Marketscreener.com
Bank Hapoalim BM Sells 11,100 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer's CEO says he's had dinner with Trump's health secretary pick, RFK Jr. - Business Insider
Pfizer Inc (PFE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Yahoo Finance
Pfizer Reports Strong 2024 Financial Results - TipRanks
Pfizer shows profit growth from cost cuts and steadier COVID sales - MSN
Pfizer CEO had dinner with RFK Jr.: ‘I’m cautiously optimistic’ in spite of his history with vaccines - Fortune
Pfizer Back In The Deal Game In 2025 - Citeline News & Insights
Pfizer (NYSE:PFE) Trading Down 1.7%Here's What Happened - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):